CClinicalTrials.gg
Sign In
Status unknownNCT03225963Updated Jul 24, 2017

Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

An observational study in Glioblastoma Multiforme and Angiogenesis, sponsored by Taichung Veterans General Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-07-24.

Sponsored by Taichung Veterans General Hospital · Observational

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
20 Years to 85 Years
Sex
All
01

Study summary

Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.

Read the detailed description

Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.

02

Conditions studied

  • Glioblastoma Multiforme
  • Angiogenesis

Browse trials for

Keywords

  • Glioblastoma
  • Bevacizumab
03

In context

Glioblastoma

1,920 studies on the registry are indexed under Glioblastoma; 450 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 188 observational studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Taichung Veterans General Hospital is the lead sponsor of 170 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Obtain peripheral blood pre-chemotherapy, mid-chemoradition and post-chemoraidtion

Inclusion criteria

  • Age older than 20 year old.
  • Glioblastoma patients who will receive chemoradiation treatment.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • RadiationChemoradiation with temozolomide
06

What researchers measure

Primary outcomes

  1. Response of bevacizumab therapy.

    Base on the image after bevacizumab therapy (after recurrence)

    Time frame: 3 months after bevacizumab therapy

07

Study locations

1 of 1 sites recruiting
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
    Recruiting
08

References and documents

Publications

  • Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res. 2003 Apr;9(4):1399-405. PubMed 12684411 ↗
  • Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E, Martinez-Sales V. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol. 2011 Mar;102(1):35-41. doi: 10.1007/s11060-010-0290-x. Epub 2010 Jul 6. PubMed 20607353 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03225963
Lead sponsor
Taichung Veterans General Hospital
Responsible party
Sponsor
First posted
Jul 21, 2017
Start date
Aug 1, 2015
Primary completion
Jul 31, 2018 (estimated)
Completion
Jul 31, 2018 (estimated)
Last update
Jul 24, 2017

Study contacts

Weir Chiang You, M.D. Ph.D.
Contact
bigjohnyou@vghtc.gov.tw
886-4-23592525 ext. 5602
Hui Lin Yeh, M.D.
Contact
yehl@vghtc.gov.tw
886-4-23592525 ext. 5621
Weir Chiang You, M.D. Ph.D.
study chair · The Institutional Review Board of Taichung Veterans General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glioblastoma→

Other studies from this sponsor

Taichung Veterans General Hospital

Start the discussion